SCHEMBL17047475

SCHEMBL17047475

N#CCc1ccc(Nc2ncc3cc(-c4cc5ccccc5s4)ccc3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 4/20 0.44
▸ PIK3CA P42336 5/20 0.43
▸ PIK3CG P48736 5/20 0.43
▸ PIK3CD O00329 2/20 0.43
▸ BRAF P15056 6/20 0.41
▸ CDK1 P06493 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ CHUK O15111 3/20 0.40
▸ IKBKG Q9Y6K9 3/20 0.40
▸ PIK3CB P42338 1/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CCNA1 P78396 1/20 0.38
▸ LIPG Q9Y5X9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17047483 0.84 PIK3CG (0.50) PIK3CAPIK3CGPIK3CDBRAFKDR
SCHEMBL17047522 0.83 PIK3CG (0.59) PIK3CAPIK3CGPIK3CDBRAFCDK1
SCHEMBL17047502 0.82 PIK3CA (0.47) PIK3CAPIK3CGPIK3CDBRAFPIK3CB
SCHEMBL17047472 0.80 PIK3CG (0.70) PIK3CAPIK3CGPIK3CDBRAFKDR
SCHEMBL18382200 0.80 MAPKAPK2 (0.51) IKBKBPIK3CAPIK3CGPIK3CDKDR
SCHEMBL7153086 0.79 ROCK1 (0.47) PIK3CAPIK3CGPIK3CDCDK1KDR
SCHEMBL17047464 0.78 PIK3CA (0.69) PIK3CAPIK3CGPIK3CDBRAFPIK3CB
SCHEMBL17047461 0.78 PIK3CA (0.43) PIK3CAPIK3CGPIK3CDBRAFPIK3CB
SCHEMBL17047495 0.78 BRAF (0.63) PIK3CAPIK3CGBRAF
SCHEMBL6172666 0.77 APP (0.57) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202374-B2 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-02-12 — — US disclosed
EP-3110801-B1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2019-01-30 — — EP disclosed
US-20170015662-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-01-19 — — US disclosed
EP-3110801-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-01-04 — — EP disclosed
WO-2015128873-A1 \"6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS\ COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202374-B2 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors PIK3CA, PI4KA, PDPK1 IKBKB 410/4885PIK3CA 1/4885PIK3CG 5/4885
US-20170015662-A1 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS PIK3CA, PI4KA, PDPK1 IKBKB 408/4885PIK3CA 1/4885PIK3CG 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback